Validation of the Clinical Assessment Scale in Autoimmune Encephalitis in Chinese Patients

The Clinical Assessment Scale in Autoimmune Encephalitis (CASE) is a scale for assessing severity in autoimmune encephalitis. We aimed to validate the CASE score in a Chinese population and evaluate its clinical significance. Patients diagnosed with autoimmune encephalitis were recruited between Jun...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in immunology 2021-12, Vol.12, p.796965-796965
Main Authors: Zhang, Yingchi, Tu, Ewen, Yao, Chenxiao, Liu, Jia, Lei, Qiang, Lu, Wei
Format: Article
Language:English
Subjects:
Adolescent
Adult
Aged
Aged, 80 and over
Asians
Autoimmune Diseases - diagnosis
Autoimmune Diseases - mortality
Autoimmune Diseases - therapy
autoimmune encephalitis
CASE scores
Child
China - epidemiology
Clinical Decision-Making
Decision Support Techniques
Encephalitis - diagnosis
Encephalitis - ethnology
Humans
Immunology
Male
Middle Aged
mRS scores
Predictive Value of Tests
Prognosis
Reproducibility of Results
Severity of Illness Index
Symptom Assessment
validation
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c465t-2ec6d29b96cc752b2ec5d29d6fd38d88c3072311f77e63456f6e2d221655d58c3
cites cdi_FETCH-LOGICAL-c465t-2ec6d29b96cc752b2ec5d29d6fd38d88c3072311f77e63456f6e2d221655d58c3
container_end_page 796965
container_issue
container_start_page 796965
container_title Frontiers in immunology
container_volume 12
creator Zhang, Yingchi
Tu, Ewen
Yao, Chenxiao
Liu, Jia
Lei, Qiang
Lu, Wei
description The Clinical Assessment Scale in Autoimmune Encephalitis (CASE) is a scale for assessing severity in autoimmune encephalitis. We aimed to validate the CASE score in a Chinese population and evaluate its clinical significance. Patients diagnosed with autoimmune encephalitis were recruited between June 2014 and May 2019 from two hospitals. CASE and modified Rankin Scale (mRS) scores were obtained. Data regarding clinical features, treatment, and available information were gathered from the hospital information system. Of the 176 patients with autoimmune encephalitis, 11 died and 14 had tumors. Ten patients received second-line treatment. The CASE scores of patients receiving second-line treatment were significantly higher (median CASE: 15) than in those receiving first-line treatment (median CASE: 8) (p2). Areas under the curve of CASE on whether functional status was poor at 1 year were 0.89 (p
doi_str_mv 10.3389/fimmu.2021.796965
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_42774458f2d940b6bc757c587c9f801b</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_42774458f2d940b6bc757c587c9f801b</doaj_id><sourcerecordid>2616279637</sourcerecordid><originalsourceid>FETCH-LOGICAL-c465t-2ec6d29b96cc752b2ec5d29d6fd38d88c3072311f77e63456f6e2d221655d58c3</originalsourceid><addsrcrecordid>eNpVkU1rXCEUhqW0NCHND-imuOxmJtdv3RSGIW0CgRb6sehGvHrMGO7V6fXeQP99nUwaEjf6es77HOVF6D3p1oxpcxHTOC5r2lGyVkYaKV6hUyIlXzFK-etn5xN0Xutd1xY3jDHxFp0wbpQwnThFv3-5IQU3p5JxiXjeAd4OKSfvBrypFWodIc_4e9OAU8abZS6HwRnwZfaw3zX7nOqhtN2lDBXwt0ZrnvoOvYluqHD-uJ-hn58vf2yvVjdfv1xvNzcrz6WYVxS8DNT0RnqvBO2bFk0HGQPTQWvPOkUZIVEpkIwLGSXQQCmRQgTRymfo-sgNxd3Z_ZRGN_21xSX7cFGmW-umOfkBLKdKcS50pMHwrpd9m6i80MqbqDvSN9anI2u_9CME3_4xueEF9GUlp529LfdWK6KFkA3w8REwlT8L1NmOqXoYBpehLNVSSSRteTHVWsmx1U-l1gni0xjS2UPE9iFie4jYHiNung_P3_fk-B8o-wdM2KNz</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2616279637</pqid></control><display><type>article</type><title>Validation of the Clinical Assessment Scale in Autoimmune Encephalitis in Chinese Patients</title><source>PubMed Central</source><creator>Zhang, Yingchi ; Tu, Ewen ; Yao, Chenxiao ; Liu, Jia ; Lei, Qiang ; Lu, Wei</creator><creatorcontrib>Zhang, Yingchi ; Tu, Ewen ; Yao, Chenxiao ; Liu, Jia ; Lei, Qiang ; Lu, Wei</creatorcontrib><description>The Clinical Assessment Scale in Autoimmune Encephalitis (CASE) is a scale for assessing severity in autoimmune encephalitis. We aimed to validate the CASE score in a Chinese population and evaluate its clinical significance. Patients diagnosed with autoimmune encephalitis were recruited between June 2014 and May 2019 from two hospitals. CASE and modified Rankin Scale (mRS) scores were obtained. Data regarding clinical features, treatment, and available information were gathered from the hospital information system. Of the 176 patients with autoimmune encephalitis, 11 died and 14 had tumors. Ten patients received second-line treatment. The CASE scores of patients receiving second-line treatment were significantly higher (median CASE: 15) than in those receiving first-line treatment (median CASE: 8) (p&lt;0.001). Twenty-two patients had poor functional status (mRS&gt;2). Areas under the curve of CASE on whether functional status was poor at 1 year were 0.89 (p&lt;0.001). Sixty patients were admitted to the intensive care unit (ICU), and the CASE scores were positively correlated with days in the ICU (r=0.58, p&lt;0.001). There was no statistically significant association between the CASE scores and relapse (p=0.39&gt;0.05). Additionally, the CASE scores were positively associated with the mRS scores (r=0.85 p&lt;0.001). The CASE score is suitable for the comprehensive assessment of Chinese patients with autoimmune encephalitis, which may help clinicians to select the appropriate intervention and estimate the disease severity and prognosis.</description><identifier>ISSN: 1664-3224</identifier><identifier>EISSN: 1664-3224</identifier><identifier>DOI: 10.3389/fimmu.2021.796965</identifier><identifier>PMID: 34975905</identifier><language>eng</language><publisher>Switzerland: Frontiers Media S.A</publisher><subject>Adolescent ; Adult ; Aged ; Aged, 80 and over ; Asians ; Autoimmune Diseases - diagnosis ; Autoimmune Diseases - mortality ; Autoimmune Diseases - therapy ; autoimmune encephalitis ; CASE scores ; Child ; China - epidemiology ; Clinical Decision-Making ; Decision Support Techniques ; Encephalitis - diagnosis ; Encephalitis - ethnology ; Humans ; Immunology ; Male ; Middle Aged ; mRS scores ; Predictive Value of Tests ; Prognosis ; Reproducibility of Results ; Severity of Illness Index ; Symptom Assessment ; validation ; Young Adult</subject><ispartof>Frontiers in immunology, 2021-12, Vol.12, p.796965-796965</ispartof><rights>Copyright © 2021 Zhang, Tu, Yao, Liu, Lei and Lu.</rights><rights>Copyright © 2021 Zhang, Tu, Yao, Liu, Lei and Lu 2021 Zhang, Tu, Yao, Liu, Lei and Lu</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c465t-2ec6d29b96cc752b2ec5d29d6fd38d88c3072311f77e63456f6e2d221655d58c3</citedby><cites>FETCH-LOGICAL-c465t-2ec6d29b96cc752b2ec5d29d6fd38d88c3072311f77e63456f6e2d221655d58c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8718556/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8718556/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27903,27904,53769,53771</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34975905$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zhang, Yingchi</creatorcontrib><creatorcontrib>Tu, Ewen</creatorcontrib><creatorcontrib>Yao, Chenxiao</creatorcontrib><creatorcontrib>Liu, Jia</creatorcontrib><creatorcontrib>Lei, Qiang</creatorcontrib><creatorcontrib>Lu, Wei</creatorcontrib><title>Validation of the Clinical Assessment Scale in Autoimmune Encephalitis in Chinese Patients</title><title>Frontiers in immunology</title><addtitle>Front Immunol</addtitle><description>The Clinical Assessment Scale in Autoimmune Encephalitis (CASE) is a scale for assessing severity in autoimmune encephalitis. We aimed to validate the CASE score in a Chinese population and evaluate its clinical significance. Patients diagnosed with autoimmune encephalitis were recruited between June 2014 and May 2019 from two hospitals. CASE and modified Rankin Scale (mRS) scores were obtained. Data regarding clinical features, treatment, and available information were gathered from the hospital information system. Of the 176 patients with autoimmune encephalitis, 11 died and 14 had tumors. Ten patients received second-line treatment. The CASE scores of patients receiving second-line treatment were significantly higher (median CASE: 15) than in those receiving first-line treatment (median CASE: 8) (p&lt;0.001). Twenty-two patients had poor functional status (mRS&gt;2). Areas under the curve of CASE on whether functional status was poor at 1 year were 0.89 (p&lt;0.001). Sixty patients were admitted to the intensive care unit (ICU), and the CASE scores were positively correlated with days in the ICU (r=0.58, p&lt;0.001). There was no statistically significant association between the CASE scores and relapse (p=0.39&gt;0.05). Additionally, the CASE scores were positively associated with the mRS scores (r=0.85 p&lt;0.001). The CASE score is suitable for the comprehensive assessment of Chinese patients with autoimmune encephalitis, which may help clinicians to select the appropriate intervention and estimate the disease severity and prognosis.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Asians</subject><subject>Autoimmune Diseases - diagnosis</subject><subject>Autoimmune Diseases - mortality</subject><subject>Autoimmune Diseases - therapy</subject><subject>autoimmune encephalitis</subject><subject>CASE scores</subject><subject>Child</subject><subject>China - epidemiology</subject><subject>Clinical Decision-Making</subject><subject>Decision Support Techniques</subject><subject>Encephalitis - diagnosis</subject><subject>Encephalitis - ethnology</subject><subject>Humans</subject><subject>Immunology</subject><subject>Male</subject><subject>Middle Aged</subject><subject>mRS scores</subject><subject>Predictive Value of Tests</subject><subject>Prognosis</subject><subject>Reproducibility of Results</subject><subject>Severity of Illness Index</subject><subject>Symptom Assessment</subject><subject>validation</subject><subject>Young Adult</subject><issn>1664-3224</issn><issn>1664-3224</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNpVkU1rXCEUhqW0NCHND-imuOxmJtdv3RSGIW0CgRb6sehGvHrMGO7V6fXeQP99nUwaEjf6es77HOVF6D3p1oxpcxHTOC5r2lGyVkYaKV6hUyIlXzFK-etn5xN0Xutd1xY3jDHxFp0wbpQwnThFv3-5IQU3p5JxiXjeAd4OKSfvBrypFWodIc_4e9OAU8abZS6HwRnwZfaw3zX7nOqhtN2lDBXwt0ZrnvoOvYluqHD-uJ-hn58vf2yvVjdfv1xvNzcrz6WYVxS8DNT0RnqvBO2bFk0HGQPTQWvPOkUZIVEpkIwLGSXQQCmRQgTRymfo-sgNxd3Z_ZRGN_21xSX7cFGmW-umOfkBLKdKcS50pMHwrpd9m6i80MqbqDvSN9anI2u_9CME3_4xueEF9GUlp529LfdWK6KFkA3w8REwlT8L1NmOqXoYBpehLNVSSSRteTHVWsmx1U-l1gni0xjS2UPE9iFie4jYHiNung_P3_fk-B8o-wdM2KNz</recordid><startdate>20211217</startdate><enddate>20211217</enddate><creator>Zhang, Yingchi</creator><creator>Tu, Ewen</creator><creator>Yao, Chenxiao</creator><creator>Liu, Jia</creator><creator>Lei, Qiang</creator><creator>Lu, Wei</creator><general>Frontiers Media S.A</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20211217</creationdate><title>Validation of the Clinical Assessment Scale in Autoimmune Encephalitis in Chinese Patients</title><author>Zhang, Yingchi ; Tu, Ewen ; Yao, Chenxiao ; Liu, Jia ; Lei, Qiang ; Lu, Wei</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c465t-2ec6d29b96cc752b2ec5d29d6fd38d88c3072311f77e63456f6e2d221655d58c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Asians</topic><topic>Autoimmune Diseases - diagnosis</topic><topic>Autoimmune Diseases - mortality</topic><topic>Autoimmune Diseases - therapy</topic><topic>autoimmune encephalitis</topic><topic>CASE scores</topic><topic>Child</topic><topic>China - epidemiology</topic><topic>Clinical Decision-Making</topic><topic>Decision Support Techniques</topic><topic>Encephalitis - diagnosis</topic><topic>Encephalitis - ethnology</topic><topic>Humans</topic><topic>Immunology</topic><topic>Male</topic><topic>Middle Aged</topic><topic>mRS scores</topic><topic>Predictive Value of Tests</topic><topic>Prognosis</topic><topic>Reproducibility of Results</topic><topic>Severity of Illness Index</topic><topic>Symptom Assessment</topic><topic>validation</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zhang, Yingchi</creatorcontrib><creatorcontrib>Tu, Ewen</creatorcontrib><creatorcontrib>Yao, Chenxiao</creatorcontrib><creatorcontrib>Liu, Jia</creatorcontrib><creatorcontrib>Lei, Qiang</creatorcontrib><creatorcontrib>Lu, Wei</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Frontiers in immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zhang, Yingchi</au><au>Tu, Ewen</au><au>Yao, Chenxiao</au><au>Liu, Jia</au><au>Lei, Qiang</au><au>Lu, Wei</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Validation of the Clinical Assessment Scale in Autoimmune Encephalitis in Chinese Patients</atitle><jtitle>Frontiers in immunology</jtitle><addtitle>Front Immunol</addtitle><date>2021-12-17</date><risdate>2021</risdate><volume>12</volume><spage>796965</spage><epage>796965</epage><pages>796965-796965</pages><issn>1664-3224</issn><eissn>1664-3224</eissn><abstract>The Clinical Assessment Scale in Autoimmune Encephalitis (CASE) is a scale for assessing severity in autoimmune encephalitis. We aimed to validate the CASE score in a Chinese population and evaluate its clinical significance. Patients diagnosed with autoimmune encephalitis were recruited between June 2014 and May 2019 from two hospitals. CASE and modified Rankin Scale (mRS) scores were obtained. Data regarding clinical features, treatment, and available information were gathered from the hospital information system. Of the 176 patients with autoimmune encephalitis, 11 died and 14 had tumors. Ten patients received second-line treatment. The CASE scores of patients receiving second-line treatment were significantly higher (median CASE: 15) than in those receiving first-line treatment (median CASE: 8) (p&lt;0.001). Twenty-two patients had poor functional status (mRS&gt;2). Areas under the curve of CASE on whether functional status was poor at 1 year were 0.89 (p&lt;0.001). Sixty patients were admitted to the intensive care unit (ICU), and the CASE scores were positively correlated with days in the ICU (r=0.58, p&lt;0.001). There was no statistically significant association between the CASE scores and relapse (p=0.39&gt;0.05). Additionally, the CASE scores were positively associated with the mRS scores (r=0.85 p&lt;0.001). The CASE score is suitable for the comprehensive assessment of Chinese patients with autoimmune encephalitis, which may help clinicians to select the appropriate intervention and estimate the disease severity and prognosis.</abstract><cop>Switzerland</cop><pub>Frontiers Media S.A</pub><pmid>34975905</pmid><doi>10.3389/fimmu.2021.796965</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1664-3224
ispartof Frontiers in immunology, 2021-12, Vol.12, p.796965-796965
issn 1664-3224
1664-3224
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_42774458f2d940b6bc757c587c9f801b
source PubMed Central
subjects Adolescent
Adult
Aged
Aged, 80 and over
Asians
Autoimmune Diseases - diagnosis
Autoimmune Diseases - mortality
Autoimmune Diseases - therapy
autoimmune encephalitis
CASE scores
Child
China - epidemiology
Clinical Decision-Making
Decision Support Techniques
Encephalitis - diagnosis
Encephalitis - ethnology
Humans
Immunology
Male
Middle Aged
mRS scores
Predictive Value of Tests
Prognosis
Reproducibility of Results
Severity of Illness Index
Symptom Assessment
validation
Young Adult
title Validation of the Clinical Assessment Scale in Autoimmune Encephalitis in Chinese Patients
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T01%3A45%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Validation%20of%20the%20Clinical%20Assessment%20Scale%20in%20Autoimmune%20Encephalitis%20in%20Chinese%20Patients&rft.jtitle=Frontiers%20in%20immunology&rft.au=Zhang,%20Yingchi&rft.date=2021-12-17&rft.volume=12&rft.spage=796965&rft.epage=796965&rft.pages=796965-796965&rft.issn=1664-3224&rft.eissn=1664-3224&rft_id=info:doi/10.3389/fimmu.2021.796965&rft_dat=%3Cproquest_doaj_%3E2616279637%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c465t-2ec6d29b96cc752b2ec5d29d6fd38d88c3072311f77e63456f6e2d221655d58c3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2616279637&rft_id=info:pmid/34975905&rfr_iscdi=true